Better Buy: Editas Medicine vs. Intellia [The Motley Fool]
Editas Medicine, Inc. (EDIT)
Last editas medicine, inc. earnings: 2/26 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.editasmedicine.com
Company Research
Source: The Motley Fool
Investors looking for high-growth, high-risk investments in the most cutting-edge areas of biotech should consider the world of gene editing. While there aren't many companies in this market to choose from, the few stocks that are dedicated to developing gene-editing drugs have massive growth potential. Both Editas Medicine ( NASDAQ:EDIT Intellia Therapeutics NASDAQ:NTLA Image source: Getty Images. The case for Editas Medicine Maybe the best way to start evaluating these two companies is by looking at their pipelines. Editas has drug candidates The company's flagship drug candidate is EDIT-0, which targets a rare form of blindness in children called leber congenital amaurosis (LCA). This is a rare genetic disorder that begins early in a child's life and affects the retina of the eye, the part responsible for color and light. As the condition progresses, newborn infants experience a severe loss of eyesight, which often leads to blindness. LCA affects two to three newborns per 00,000.
Show less
Read more
Impact Snapshot
Event Time:
EDIT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EDIT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EDIT alerts
High impacting Editas Medicine, Inc. news events
Weekly update
A roundup of the hottest topics
EDIT
News
- Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Evercore ISI from $7.00 to $5.00. They now have an "outperform" rating on the stock.MarketBeat
- Editas Medicine, Inc. (NASDAQ: EDIT) was downgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "underweight" rating.MarketBeat
- Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Royal Bank of Canada from $5.00 to $4.00. They now have a "sector perform" rating on the stock.MarketBeat
- Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Barclays PLC from $5.00 to $3.00. They now have an "equal weight" rating on the stock.MarketBeat
- Editas Medicine, Inc. (NASDAQ: EDIT) had its "neutral" rating re-affirmed by analysts at Chardan Capital.MarketBeat
EDIT
Earnings
- 11/4/24 - Beat
EDIT
Sec Filings
- 12/17/24 - Form 8-K
- 12/12/24 - Form 8-K
- 12/10/24 - Form 8-K
- EDIT's page on the SEC website